Smallpox treatment involves the use of vaccination, quarantine, tracing of contacts, and isolation to provide immunity and break the chain of infection. Smallpox vaccines are made from vaccinia virus, a poxvirus related to smallpox. The smallpox vaccine induces protective immunity, and prior vaccination with the smallpox vaccine also provides some cross protection against monkeypox. Owing to its high mortality rates, smallpox was targeted for eradication by the World Health Organization (WHO). The last naturally occurring case was in 1977, and the disease was declared eradicated in 1980. However, smallpox is still considered a potential bioterrorism agent, driving research and development of new therapeutics and vaccines. The global Smallpox Treatment Market is estimated to be valued at US$ 68.7 Mn in 2023 and is expected to exhibit a CAGR of 1.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the smallpox treatment market is the rising preventive vaccination programs by governments and non-profit organizations across the globe. This is due to smallpox’s potential as a bioterror agent. For instance, the U.S. Centers for Disease Control and Prevention (CDC) recommends smallpox vaccination for individuals who work directly with orthopoxviruses in research laboratories. Similarly, the Canadian government offers smallpox vaccination to laboratory workers engaged in virus research. Various non-profit organizations are also raising awareness about preventive smallpox vaccination. For example, the Nuclear Threat Initiative, a non-profit organization working to reduce global threats from nuclear, biological and chemical weapons, is supporting research on new smallpox vaccines and therapeutics. Such initiatives are fueling demand for smallpox treatments and vaccines, driving the market growth.

Porter’s Analysis

Threat of new entrants: Low. Require substantial R&D investments and strict regulatory approvals to develop smallpox vaccines and treatments.

Bargaining power of buyers: Moderate. Limited treatment options drives demand but prices are regulated by governments.

Bargaining power of suppliers: Low. Requires specialized expertise and scarce resources to manufacture smallpox vaccines.

Threat of new substitutes: Low. No substitutes available for smallpox treatment given disease status.

Competitive rivalry: Moderate. Competition between established players to develop new and improved vaccines/products.

Key Takeaways

The global Smallpox Treatment Market Growth is expected to witness high growth over the forecast period. North America currently dominates the market due to supportive government initiatives and presence of prominent market players in the region.

Regional analysis:

North America holds the largest share of the smallpox treatment market due to growing government funding for research activities and presence of key market players in the US. Europe is expected to show lucrative growth owing to rising initiatives to strengthen preparedness against smallpox outbreaks.

Key players:

Key players operating in the smallpox treatment market include SIGA Technologies Inc., Bavarian Nordic A/S, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Emergent BioSolutions Inc., Novartis International AG, GlaxoSmithKline plc, Sanofi Pasteur SA, Merck & Co. Inc., Pfizer Inc., Bharat Biotech International Ltd., BioCryst Pharmaceuticals Inc., Chimerix Inc., Nanotherapeutics Inc., Bavarian Nordic A/S. SIGA Technologies Inc. dominates the market with its smallpox antiviral – Tecovirimat.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it